Healthcare provider profile · identity verified

Irfan Khan, MD

Internal Medicine · CAMDEN, NJ · NPI 1922627280

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	662	82
Amlodipine Besylate	Amlodipine Besylate	498	62
Mirtazapine	Mirtazapine	405	53
Tamsulosin Hcl	Tamsulosin Hcl	293	40
Eliquis	Apixaban	220	29
Gabapentin	Gabapentin	201	28
Clopidogrel	Clopidogrel Bisulfate	188	19
Lisinopril	Lisinopril	181	21
Levothyroxine Sodium	Levothyroxine Sodium	180	24
Metoprolol Succinate	Metoprolol Succinate	173	23
Famotidine	Famotidine	162	24
Sertraline Hcl	Sertraline Hcl	157	20
Carvedilol	Carvedilol	140	19
Furosemide	Furosemide	135	25
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	128	23
Divalproex Sodium	Divalproex Sodium	127	16
Metformin Hcl	Metformin Hcl	109	12
Quetiapine Fumarate	Quetiapine Fumarate	108	14
Escitalopram Oxalate	Escitalopram Oxalate	102	17
Finasteride	Finasteride	98	12
Latanoprost	Latanoprost	93	20
Levetiracetam	Levetiracetam	92	14
Metoprolol Tartrate	Metoprolol Tartrate	91	13
Losartan Potassium	Losartan Potassium	89	15
Omeprazole	Omeprazole	88	17
Risperidone	Risperidone	83	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	79	23
Pantoprazole Sodium	Pantoprazole Sodium	79	23
Nifedipine Er	Nifedipine	78	suppressed
Jardiance	Empagliflozin	71	11
Donepezil Hcl	Donepezil Hcl	69	11
Duloxetine Hcl	Duloxetine Hcl	69	suppressed
Olanzapine	Olanzapine	62	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	60	suppressed
Lactulose	Lactulose	58	11
Pravastatin Sodium	Pravastatin Sodium	58	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	57	suppressed
Midodrine Hcl	Midodrine Hcl	55	suppressed
Montelukast Sodium	Montelukast Sodium	52	suppressed
Hydralazine Hcl	Hydralazine Hcl	50	suppressed
Trazodone Hcl	Trazodone Hcl	49	suppressed
Humalog Kwikpen U-100	Insulin Lispro	48	suppressed
Benztropine Mesylate	Benztropine Mesylate	44	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	37	suppressed
Baclofen	Baclofen	36	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	35	suppressed
Potassium Chloride	Potassium Chloride	35	suppressed
Trulicity	Dulaglutide	35	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	32	suppressed
Memantine Hcl	Memantine Hcl	31	suppressed
Haloperidol	Haloperidol	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	29	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	29	16
Torsemide	Torsemide	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	26	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	25	13
Haloperidol Lactate	Haloperidol Lactate	25	suppressed
Simvastatin	Simvastatin	25	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Amantadine	Amantadine Hcl	23	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	23	suppressed
Rexulti	Brexpiprazole	23	suppressed
Xarelto	Rivaroxaban	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Atenolol	Atenolol	19	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	19	suppressed
Labetalol Hcl	Labetalol Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Sodium Chloride	0.9 % Sodium Chloride	18	suppressed
Topiramate	Topiramate	18	suppressed
Myrbetriq	Mirabegron	17	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	17	suppressed
Prednisolone Acetate	Prednisolone Acetate	16	suppressed
Prednisone	Prednisone	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	15	suppressed
Lumigan	Bimatoprost	15	suppressed
Tradjenta	Linagliptin	15	suppressed
Xifaxan	Rifaximin	15	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Acetazolamide	Acetazolamide	13	suppressed
Allopurinol	Allopurinol	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Anastrozole	Anastrozole	13	suppressed
Carbamazepine	Carbamazepine	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Risperdal Consta	Risperidone Microspheres	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Fondaparinux Sodium	Fondaparinux Sodium	11	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	11	suppressed
Icosapent Ethyl	Icosapent Ethyl	11	suppressed
Methenamine Hippurate	Methenamine Hippurate	11	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Rivastigmine	Rivastigmine Tartrate	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error